Cargando…
Pharmaceutical treatment of acute bipolar depression
The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry. The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination. However, the usefulness of antidepressants in bipolar depression remains controversial; positive data a...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medicine Reports Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950046/ https://www.ncbi.nlm.nih.gov/pubmed/20948837 http://dx.doi.org/10.3410/M2-47 |
_version_ | 1782187618697478144 |
---|---|
author | Fountoulakis, Konstantinos N |
author_facet | Fountoulakis, Konstantinos N |
author_sort | Fountoulakis, Konstantinos N |
collection | PubMed |
description | The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry. The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination. However, the usefulness of antidepressants in bipolar depression remains controversial; positive data are available for fluoxetine but negative results have been published for paroxetine. Accumulated knowledge so far suggests that bipolar patients need continuous administration of an antimanic agent even during the acute depressive phase. Although our knowledge is indeed limited, the development of guidelines for polypharmacy is necessary and should be done as soon as possible. |
format | Text |
id | pubmed-2950046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Medicine Reports Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-29500462010-10-14 Pharmaceutical treatment of acute bipolar depression Fountoulakis, Konstantinos N F1000 Med Rep Review Article The treatment of bipolar depression is one of the most challenging fields in contemporary psychiatry. The best data concern the antipsychotics quetiapine and the olanzapine-fluoxetine combination. However, the usefulness of antidepressants in bipolar depression remains controversial; positive data are available for fluoxetine but negative results have been published for paroxetine. Accumulated knowledge so far suggests that bipolar patients need continuous administration of an antimanic agent even during the acute depressive phase. Although our knowledge is indeed limited, the development of guidelines for polypharmacy is necessary and should be done as soon as possible. Medicine Reports Ltd 2010-06-23 /pmc/articles/PMC2950046/ /pubmed/20948837 http://dx.doi.org/10.3410/M2-47 Text en © 2010 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
spellingShingle | Review Article Fountoulakis, Konstantinos N Pharmaceutical treatment of acute bipolar depression |
title | Pharmaceutical treatment of acute bipolar depression |
title_full | Pharmaceutical treatment of acute bipolar depression |
title_fullStr | Pharmaceutical treatment of acute bipolar depression |
title_full_unstemmed | Pharmaceutical treatment of acute bipolar depression |
title_short | Pharmaceutical treatment of acute bipolar depression |
title_sort | pharmaceutical treatment of acute bipolar depression |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950046/ https://www.ncbi.nlm.nih.gov/pubmed/20948837 http://dx.doi.org/10.3410/M2-47 |
work_keys_str_mv | AT fountoulakiskonstantinosn pharmaceuticaltreatmentofacutebipolardepression |